326 related articles for article (PubMed ID: 22515291)
1. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
3. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma.
Cho H; Kim JY; Oh YL
Pathol Int; 2018 Nov; 68(11):605-613. PubMed ID: 30350394
[TBL] [Abstract][Full Text] [Related]
8. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
10. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential.
Papotti M; Rodriguez J; De Pompa R; Bartolazzi A; Rosai J
Mod Pathol; 2005 Apr; 18(4):541-6. PubMed ID: 15529186
[TBL] [Abstract][Full Text] [Related]
13. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
14. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
15. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Nakamura N; Erickson LA; Jin L; Kajita S; Zhang H; Qian X; Rumilla K; Lloyd RV
Endocr Pathol; 2006; 17(3):213-23. PubMed ID: 17308358
[TBL] [Abstract][Full Text] [Related]
17. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
19. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]